Interesting review. What makes it interesting is that you clearly try to be objective but still see everything in a very one sided way. Like many here, you keep believing that the slow adoption is a result of poor education, etc...
And yet, there are clearly well educated providers, who follow the latest research and ignore Provenge. See for example this report from ASCO 212:
2012 Jun 28, Jeffrey Kirshner, MD
" [...] Many of my prostate cancer patients are still responding to abiraterone after progressing on Taxotere. [..] "
Why Provenge is not even mentioned in his list this year nor last year? Clearly it's not a case of uninformed, reimbursement, etc... Another member of world wide anti-DnDn conspiracy?